Overview
Community health education is a foundation of global efforts to eliminate elephantiasis, also known as Lymphatic Filariasis (LF). CHE enforces the use of mass drug administration (MDA), promotes good adherence and coverage, strengthens vector control and hygiene behaviours, reduces stigma, and sustains surveillance gains long after drug campaigns end.
The WHO's Global Programme to Eliminate Lymphatic Filariasis (GPELF) data shows substantial progress, although gaps in awareness, participation, and mass administration vigilance continue to threaten success, making well-designed, locally led education indispensable.
Background
Elephantiasis, also known as lymphatic filariasis (LF) or lymphoedema, is a mosquito-borne neglected tropical disease caused by parasitic worms Wuchereria bancrofti, Brugia malayi, or Brugia timori. LF occurs when a mosquito infected with the disease bites someone repeatedly, and the parasitic worms infect the lymphatic system.1
The worms grow and reproduce, releasing millions of worms into the bloodstream. People with LF present swelling of different parts of the body, such as oedema or hydrocele. In addition, it causes weakness of the immune system, hence making people more prone to thickened skin and bacterial infections.1
The diagnosis is made by collecting the medical history of the person, as well as their physical examination. Currently, there is no specific treatment; therefore, the treatment is focused on reducing the swelling and taking care of the skin to avoid infections. All of this makes the prevention of the disease crucial.1
The WHO GPELF delivered over 9.7 billion preventive treatments in 2000, and by 2018, the number of infected persons had declined to 51 million (74%). In 2023, 3939 of 72 endemic countries still required preventive chemotherapy in some implementation units. More than 21 countries as of 2021 had achieved validation of elimination as a public health problem.
The elimination package combines:
- The application of preventive chemotherapy as mass drug administration (MDA), which involves applying specific treatments to people at risk of getting the disease
- Measures to diminish the number of mosquitoes in places at risk (vector control)
- Morbidity management and disability prevention (MMDP)
Why is community health education important?
Community health education is essential because it helps with the following actions:
- Engagement with mass drug administration coverage, program demands, and trusted tailored messages to improve uptake2
- Support around the community when it is necessary to change the treatments3
- It improves access and participation
- It reduces stigma and encourages early seeking behaviour4
- Sustain post-elimination vigilance5
Resources of community health education
- Co-create communities through participatory design with local leaders, women, youth, children, and people affected by LF to create simple, culturally resonant messages on radio or social media2
- Use community health workers and school networks who are most trusted and reliable for door-to-door counselling and mobilisation for MDA6
- Explain the reasons and clarify mosquito transmission, the role of asymptomatic infection, and the rationale for regimens, adverse effects, and when to seek help1
- Promote long-lasting insecticidal net use (LLINs), environmental mosquito control, and MMDP self-care4
- The community health workers target hard-to-reach and multiple touch points, such as faith centres, markets, and worksites7
- Follow up on awareness, reach, and compliance during each MDA round; the use of rapid feedback to adjust messaging and logistics (WHO GPELF provide templates/indicators for program monitoring)
Current global evidence linking community health education to outcomes
- Community engagement coverage and compliance are associated with WHO’s ≥65-85% epidemiologic coverage targets8
- Empower community networks (CHW systems) to help maintain continuity and advocate for support2,3
Practical, field-ready education package
Key messages
- LF is spread by mosquitoes; infected persons show no symptoms and can pass it on
- Take the preventive chemotherapy when the opportunity arises
- Use a long-lasting insecticide-treated net every night to prevent mosquito bites
- Maintain a clean environment to reduce mosquito breeding sites
- If the swelling occurs on the legs, scrotum, or breasts, don't hide it; rather, visit the health centre for help1,2
Channels
- House-to-house counselling, school sessions, radio call-ins, faith gatherings, market outreaches, and WhatsApp short videos with local dialects
- Who delivers: Community health workers/CDDs, teachers, nurses, religious/traditional leaders, and persons affected by LF trained as peer educators6,7
Timing
- Pre-MDA mobilisation (2-4 weeks)
- Daily reminder during MDA
- Post-MDA follow-up
- Periodic micro-campaigns between rounds for LLINS/MMDP2,3,4
Policy recommendations
- Adoption of communication toolkits where necessary, emphasising safety, benefits, and management pathways
- Institutionalise community health education as a funded line item
- Promote and protect professional CHW/CDD networks with adequate training, supervision, and incentives
- Mandate post-validation education and surveillance
- Integrate the program with malaria, WASH, and primary care platforms to share channels and budgets2,3,4
Summary
Global elimination of elephantiasis could be achievable if communities were well informed, heard, and empowered. Health education transforms one-off campaigns into durable, community-owned public health systems that deliver high mass drug administration coverage, safer adoption of new regimens, stigma reduction, and early detection. There is no elimination without education.
References
- Molyneux D. Lymphatic Filariasis (Elephantiasis) Elimination: A public health success and development opportunity. Filaria J [Internet]. 2003 [cited 2025 Sep 8]; 2:13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC200964/.
- Krentel, Alison, et al. “Keeping Communities at the Centre of Efforts to Eliminate Lymphatic Filariasis: Learning from the Past to Reach a Future Free of Lymphatic Filariasis.” International Health, vol. 13, no. Supplement_1, Dec. 2020, pp. S55–59. Available from: https://academic.oup.com/inthealth/article/13/Supplement_1/S55/6043672.
- Tripathi, Bhupendra, et al. “Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned.” The American Journal of Tropical Medicine and Hygiene. Available from: https://www.ajtmh.org/view/journals/tpmd/106/5_Suppl/article-p29.xml.
- Njomo DW, Kibe LW, Kimani BW, Okoyo C, Omondi WP, Sultani HM. Addressing barriers of community participation and access to mass drug administration for lymphatic filariasis elimination in Coastal Kenya using a participatory approach. PLOS Neglected Tropical Diseases [Internet]. 2020 [cited 2025 Sep 8]; 14(9):e0008499. Available from: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0008499.
- Couteaux C, Demaneuf T, Bien L, Munoz M, Worms B, Chésimar S, et al. Postelimination Cluster of Lymphatic Filariasis, Futuna, 2024 - Volume 31, Number 3—March 2025 - Emerging Infectious Diseases journal - CDC [Internet]. [cited 2025 Sep 8]. Available from: https://wwwnc.cdc.gov/eid/article/31/3/24-1317_article.
- Inobaya, Marianette T., et al. “Mass Drug Administration and the Sustainable Control of Schistosomiasis: Community Health Workers Are Vital for Global Elimination Efforts.” International Journal of Infectious Diseases, vol. 66, Jan. 2018, pp. 14–21. Available from: https://doi.org/10.1016/j.ijid.2017.10.023.
- Taylor, Melissa, et al. “Community Views on Mass Drug Administration for Filariasis: A Qualitative Evidence Synthesis.” The Cochrane Database of Systematic Reviews, vol. 2022, no. 2, Feb. 2022, p. CD013638. Available from: https://doi.org/10.1002/14651858.CD013638.pub2.
- Willis, Gabriela A., et al. “A Community Survey of Coverage and Adverse Events Following Country-Wide Triple-Drug Mass Drug Administration for Lymphatic Filariasis Elimination, Samoa 2018.” PLOS Neglected Tropical Diseases, vol. 14, no. 11, Nov. 2020, p. e0008854. Available from: https://doi.org/10.1371/journal.pntd.0008854.

